LEPU BIOPHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.83 HKD | +6.19% |
|
-5.82% | +38.48% |
| 12/04 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
| 27/03 | Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 10,772 | 6,350 | 8,946 | - | - |
| Enterprise Value (EV) 1 | 10,786 | 6,350 | 9,572 | 9,766 | 8,489 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 692 x | 28.2 x | 32 x | 33.1 x | 9.05 x |
| EV / Revenue | 693 x | 28.2 x | 34.2 x | 36.1 x | 8.58 x |
| EV / EBITDA | -19.4 x | -22 x | -45.9 x | -31.4 x | -74.4 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | 12 x | - | 14.2 x | 27 x | 53.9 x |
| Nbr of stocks (in thousands) | 16,59,445 | 16,59,445 | 16,59,445 | - | - |
| Reference price 2 | 6.491 | 3.827 | 5.391 | 5.391 | 5.391 |
| Announcement Date | 17/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 15.57 | 225.4 | 279.8 | 270.3 | 989 |
| EBITDA 1 | -555.9 | -288.4 | -208.3 | -310.6 | -114.2 |
| EBIT 1 | -704.5 | -391 | -371.3 | -470.8 | -267.7 |
| Operating Margin | -4,524.03% | -173.48% | -132.74% | -174.19% | -27.07% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 17/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | 14.2 | - | 626 | 820 | - |
| Net Cash position 1 | - | - | - | - | 457 |
| Leverage (Debt/EBITDA) | -0.0255 x | - | -3.003 x | -2.64 x | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -79.3% | - | -34% | -61.8% | -65.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 2 | 0.5400 | - | 0.3800 | 0.2000 | 0.1000 |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 17/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.391
CNY
Average target price
4.613
CNY
Spread / Average Target
-14.43%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +38.48% | 1.24B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- 2157 Stock
- Financials Lepu Biopharma Co., Ltd.